Skip to main content
Premium Trial:

Request an Annual Quote

Illumina and GenoLogics Will Co-Market Next-Gen Sequencing Informatics Software

Premium

This story was originally published Feb. 2.

Illumina and GenoLogics, which designs laboratory information management system software, have entered into a co-selling agreement, GenoLogics said last week. Under the terms of the deal, Illumina will market a version of GenoLogics' Geneus LIMS software that is pre-configured for its next-gen sequencing systems and TruSeq sample prep kits.

GenoLogics said the software will enable customers to track library preparation and instrument runs, and prepare basic reports in weeks rather than months.

GenoLogics' CEO Michael Ball said that the agreement follows on a previous preferred partner agreement that has allowed the company to work with Illumina on software that is "complementary" to its hardware and sample prep kits. "This enables next-generation sequencing labs to deploy instrumentation and data management solutions simultaneously."

The company has also partnered with Pacific Biosciences for data handling and analysis (IS 2/16/2010).

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.